RxDoctor Payments Data

Carolyn Gbur, MD

Cardiovascular Disease · Perrysburg, OHNPI 1386646685

Payments from drug & device makers

$10,339in general payments, 2019–2025

Across 497 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$935
  • Johnson & Johnson$914
  • Boehringer Ingelheim$852
  • Amgen$549
  • Sanofi-aventis U.S. LLC$514
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$10,15898%
  • Education$1812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,339 in reported general payments places this provider in the 75th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$277,909
Medicare patients
1,026
Services billed
3,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban763$740,963
XareltoRivaroxaban233$276,077
FarxigaDapagliflozin Propanediol172$158,251
Repatha SureclickEvolocumab192$129,031
EntrestoSacubitril/Valsartan99$119,326
JardianceEmpagliflozin102$115,159
CamzyosMavacamten11$86,993
MultaqDronedarone Hcl20$28,986
BrilintaTicagrelor37$27,805
CorlanorIvabradine Hcl38$27,162
Praluent PenAlirocumab38$25,384
VerquvoVericiguat16$14,242
Metoprolol Succinate970$13,650
LivaloPitavastatin Calcium13$10,122
Ranolazine ErRanolazine86$9,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$484$740,963763 claims
Johnson & JohnsonXarelto$914$276,077233 claims
AstraZenecaFarxiga, Brilinta$1,509$186,056209 claims
NovartisEntresto$935$119,32699 claims
Boehringer IngelheimJardiance$852$115,159102 claims
E.r. Squibb & Sons, L.L.C.Camzyos$306$86,99311 claims
Sanofi-aventis U.S. LLCMultaq$514$28,98620 claims
AmgenCorlanor$549$27,16238 claims
MerckVerquvo$441$14,24216 claims
Kowa Pharmaceuticals America, Inc.Livalo$29$10,12213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Perrysburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →